0557330 20250603154156.420220516235959.9 85129879793 000793383600002 10.1038/s41598-022-11250-4 12 s. cav_un_epca*03865942045-232212Nature Publishing Group covid-19 vaccine efficacy inter-dose period epidemic modelling vaccination second dose delay cav_un_auth*1103974 Berec Luděk BC-A ENTU - Ekologie Ecology Insect Ecology K Biologické centrum AV ČR, v. v. i. cav_un_auth*0072028 Levínský R. CZ cav_un_auth*0430347 Weiner J. CZ cav_un_auth*0101206 Šmíd Martin UTIA-B Ekonometrie Department of Econometrics E E Department of Econometrics Ústav teorie informace a automatizace AV ČR, v. v. i. cav_un_auth*0100794 Neruda Roman UIVT-O Oddělení strojového učení Department of Machine Learning Department of Machine Learning Ústav informatiky AV ČR, v. v. i. cav_un_auth*0231277 Vidnerová Petra UIVT-O Oddělení strojového učení Department of Machine Learning Department of Machine Learning Ústav informatiky AV ČR, v. v. i. cav_un_auth*0402629 Suchopárová Gabriela UIVT-O Oddělení strojového učení Department of Machine Learning CZ Ústav informatiky AV ČR, v. v. i. textový soubor https://www.nature.com/articles/s41598-022-11250-4.pdf TL04000282 GA TA ČR CZ cav_un_auth*0414828 Following initial optimism regarding potentially rapid vaccination, delays and shortages in vaccine supplies occurred in many countries during spring 2021. Various strategies to counter this gloomy reality and speed up vaccination have been set forth, of which the most popular has been to delay the second vaccine dose for a longer period than originally recommended by the manufacturers. Controversy has surrounded this strategy, and overly simplistic models have been developed to shed light on this issue. Here we use three different epidemic models, all accounting for then actual COVID- 19 epidemic in the Czech Republic, including the real vaccination rollout, to explore when delaying the second vaccine dose by another 3 weeks from 21 to 42 days is advantageous. Using COVID-19-related deaths as a quantity to compare various model scenarios, we find that the way of vaccine action at the beginning of the infection course (preventing infection and symptoms appearance), mild epidemic and sufficient vaccine supply rate call for the original inter-dose period of 21 days regardless of vaccine efficacy. On the contrary, for the vaccine action at the end of infection course (preventing severe symptoms and death), severe epidemic and low vaccine supply rate, the 42-day inter-dose period is preferable, at any plausible vaccine efficacy. WOS FN 30000 30100 30102 2023 7 UIVT-O 10000 10200 10201 UTIA-B 10000 10200 10201 4 A 4a 20250224113402.0 UIVT-O IN RVO:60077344 RVO:67985556 RVO:67985807 https://hdl.handle.net/11104/0333827 1 cav_un_auth*0295059 Jihočeská univerzita České Budějovice JU České Budějovice CZ S 7638 3+4 Article Multidisciplinary Sciences A MULTIDISCIPLINARYSCIENCES 4.9 0.9 4.5 1.05758 1.132 738367 0.973 4.400 21127 Q2 71 Q2 Q2 1.06 Q1 70.5 2022 Soubory v repozitáři: 0557330.pdf 85129879793 SCOPUS 35538118 PUBMED 000793383600002 WOS textový soubor cav_un_epca*0386594 Scientific Reports 2045-2322 2045-2322 Roč. 12 č. 1 2022 Nature Publishing Group